Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.33 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152211 | 0.76 | HPGDS (0.50) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL17701194 | 0.76 | HPGDS (0.42) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28328001 | 0.75 | HPGDS (0.38) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL533033 | 0.74 | LTA4H (0.50) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL722557 | 0.74 | LTA4H (0.64) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL100765 | 0.72 | HPGDS (0.46) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28362996 | 0.72 | LTA4H (0.62) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28320605 | 0.72 | LTA4H (0.62) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28257875 | 0.72 | LTA4H (0.62) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28328000 | 0.71 | HPGDS (0.35) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | HPGDS 3004/4885LTA4H 1858/4885CHRNA7 3266/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | HPGDS 3004/4885LTA4H 1858/4885CHRNA7 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.